Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Diabetes rivals combine

Diabetes rivals combine

The major rivalry in the field of cellular implants to treat Type I insulin dependent diabetes has become a collaboration, as CytoTherapeutics Inc.

Both companies have been working on implantable delivery systems containing insulin-producing islet cells to treat diabetes. CTII's membranes consist of either hollow fibers or a flat-sheet diffusion device containing islets. Oxygen, nutrients and

Read the full 598 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE